There are 8 resources available
CDK4-6 inhibitors in patients with early HR positive / HER2 negative breast cancer: Successes and failures
Presenter: G. Curigliano, IT
Session: Session 1 – CDK4-6 inhibitors in early breast cancer
Resources:
Slides
Webcast
Incorporating CDK 4-6 inhibitors in patients with high-risk HR positive/ HER2 negative early breast cancer: Challenging clinical scenarios with the use of PARP inhibitors and immune-checkpoint inhibitors
Presenter: D. Trapani, IT
Session: Session 1 – CDK4-6 inhibitors in early breast cancer
Resources:
Slides
Webcast
Role of CDK4-6 inhibitors in patients with endocrine sensitive HR positive / HER2 negative metastatic breast cancer
Presenter: B. Pistilli, FR
Session: Session 2 – CDK4-6 inhibition in advanced breast cancer
Resources:
Slides
Webcast
Role of CDK 4-6 inhibitors in patients with endocrine resistant HR positive /HER2 negative metastatic breast cancer
Presenter: L. Del Mastro, IT
Session: Session 2 – CDK4-6 inhibition in advanced breast cancer
Resources:
Slides
Webcast
New agents and new combinations in endocrine resistant HR positive /HER2 negative metastatic breast cancer
Presenter: G. Curigliano, IT
Session: Session 2 – CDK4-6 inhibition in advanced breast cancer
Resources:
Slides
New generation clinical trials with CDK 4-6 inhibitors in the adjuvant setting
Presenter: D. Trapani, IT
Session: Session 3 – Biomarkers and clinical and pathological features of response to CDK 4-6 inhibitors
Resources:
Slides
Genomic and transcriptomic landscape of patients receiving CDK 4-6 inhibitors
Presenter: L. Del Mastro, IT
Session: Session 3 – Biomarkers and clinical and pathological features of response to CDK 4-6 inhibitors
Resources:
Slides
Webcast
Management of adverse events of CDK 4-6 inhibitors in early and metastatic breast cancer: Balancing efficacy and toxicity
Presenter: B. Pistilli, FR
Session: Clinical Practice Session – CDK4-6 Inhibitors in breast cancer
Resources:
Slides